Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dabrafenib + trametinib study in BRAF V600E-mutated rare cancers
NL-OMON50511Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in anaplastic thyroid cancer (ATC), biliary cancer, gastrointestinal stromal tumor (GIST) and 5 more, sponsored by Novartis. Primary endpoint: overall response rate. Started Feb 2015; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)biliary cancergastrointestinal stromal tumor (GIST)gliomagerm cell tumor (GCT)
Beyond the preview
Go deeper on NL-OMON50511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50511.